Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | MEN1 | O00255 | 4/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | GLA | P06280 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | HTR3A | P46098 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2611279 | 0.90 | RXFP1 (0.56) | RXFP1ALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL2118590 | 0.88 | TP53 (0.57) | RXFP1ALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL2115751 | 0.84 | ALDH1A1 (0.78) | RXFP1ALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL22201487 | 0.83 | RXFP1 (0.86) | RXFP1ALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL4548108 | 0.81 | TP53 (0.62) | RXFP1ALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL2118929 | 0.80 | ALDH1A1 (0.59) | ALDH1A1LMNAHSD17B10GAAHPGD | |
| SCHEMBL2116506 | 0.79 | HTR3A (0.62) | RXFP1ALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL11798445 | 0.75 | ALDH1A1 (0.67) | RXFP1ALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL4252448 | 0.75 | SMN1; SMN2 (0.66) | RXFP1ALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL8480237 | 0.75 | MEN1 (0.73) | RXFP1ALDH1A1KMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160039789-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2016-02-11 | — | — | US | disclosed |
| US-20160039789-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2016-02-11 | — | — | US | disclosed |
| US-8765773-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765773-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| WO-2012054332-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| US-20120094997-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094997-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC5 | RXFP1 414/4885ALDH1A1 298/4885KMT2A 35/4885 |
| US-20160039789-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC5 | RXFP1 414/4885ALDH1A1 298/4885KMT2A 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.